No headlines found.
Globe Newswire (Thu, 26-Mar 8:00 AM ET)
Globe Newswire (Tue, 17-Mar 8:00 AM ET)
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
Globe Newswire (Tue, 10-Mar 8:00 AM ET)
Globe Newswire (Mon, 9-Mar 8:00 AM ET)
Globe Newswire (Tue, 3-Mar 8:30 AM ET)
Globe Newswire (Tue, 3-Mar 8:00 AM ET)
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
Globe Newswire (Tue, 24-Feb 8:00 AM ET)
Globe Newswire (Tue, 10-Feb 8:00 AM ET)
Daxor Corporation Announces $9 Million Registered Direct Offering
Globe Newswire (Fri, 23-Jan 8:00 AM ET)
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
Daxor - Closed End trades on the NASDAQ stock market under the symbol DXR.
As of April 2, 2026, DXR stock price climbed to $9.70 with 15,548 million shares trading.
DXR has a market cap of $56.52 million. This is considered a Micro Cap stock.
In the last 3 years, DXR traded as high as $14.76 and as low as $6.55.
The top ETF exchange traded funds that DXR belongs to (by Net Assets): VTI.
DXR has outperformed the market in the last year with a return of +19.2%, while the SPY ETF gained +18.2%. However, in the most recent history, DXR shares have underperformed the stock market with its stock returning -34.2% in the last 3 month period and -12.7% for the last 2 week period, while SPY has returned -3.6% and -0.6%, respectively.
DXR support price is $9.19 and resistance is $10.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DXR shares will trade within this expected range on the day.